CCR5, that can protect against HIV infection. The mutation probably originated in
Europe among survivors of the bubonic plague. The mutated gene prevents the plague
bacteria from attaching to cell membranes and, therefore, from entering and infecting
body cells.
Although the HIV virus is very different from the bacteria that causes the plague, both
diseases affect the exact same cells and use the same method of infection. The presence
of the mutated gene in descendants of plague survivors helps prevent them from
contracting AIDS. Pharmaceutical companies are using this information as the basis for
a new approach to AIDS prevention. This could be very important in areas of the world
where the mutation is scarce or absent, such as Africa.
Imagine that a pharmaceutical company was successful at producing a drug based on
the CCR5 gene product that is effective at preventing the contraction of AIDS.
However, shortly after the drug has been in use, patients and doctors report that the drug
is not as effective as it once was. What is the most likely explanation for this result?
A) The people taking the drug have built up a tolerance to the drug.
B) Some HIV viruses have genetic variations in the RNA genome that provide
resistance to the actions of the drug.
C) The HIV virus gained mutations in its DNA genome in order to become resistant to
the actions of the drug.
D) The DNA of white blood cells of the people taking the drug have mutated to become
resistant to the drug.
Why is a newly molted crab unusually slow and clumsy?
A) Its new exoskeleton cannot support the forces that its muscles generate.
B) It temporarily lacks an exoskeleton.
C) Its muscles are still forming their connections with the new exoskeleton.
D) Its neurons are still forming their connections with the new muscles.